EPH131 Estimation of the Population of Patients Eligible for Pirtobrutinib after Covalent Bruton Tyrosine Kinase Inhibitor (CBTKI) Discontinuation in the United States von Zhang, K.H., Winfree, K., Taipale, K.L., Muehlenbein, C.E., Panjic, E.H., Graham, C.

Volltext

PCN91 COST-EFFECTIVENESS OF IMMUNOTHERAPY-BASED DRUG REGIMENS FOR THE INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER von Aggarwal, H., Zhang, S., Muehlenbein, C.E., Winfree, K.B., Zhu, Y., Baker, T.

Volltext

PCN131 COST EFFECTIVENESS OF PEMETREXED IN COMBINATION WITH PEMBROLIZUMAB AND PLATINUM CHEMOTHERAPY (PEM+PEMBRO+PLAT), FOR INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOU... von Aggarwal, H., Muehlenbein, C.E., Klein, T., Winfree, K.B., Bly, C.A., Zhu, Y., Perk, S., Smolen, L.J.

Volltext

PCN98 A BUDGET IMPACT (BI) ANALYSIS OF PEMETREXED IN COMBINATION WITH PEMBROLIZUMAB AND PLATINUM CHEMOTHERAPY FOR INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS (NSQ) N... von Aggarwal, H., Muehlenbein, C.E., Klein, T., Winfree, K.B., Bly, C.A., Zhu, Y., Perk, S., Smolen, L.J.

Volltext

Supplementary Material for: Safety of extended pirtobrutinib exposure in relapsed and/or refractory B-cell malignancies von L.E., Roeker, C.C., Coombs, N.N., Shah, W., Jurczak, J.A., Woyach, C.Y., Cheah, K., Patel, K., Maddocks, Y., Wang, P.L., Zinzani, T., Munir, Y., Koh, M.C., Thompson, C.E., Muehlenbein, C., Wang, R., Sizelove, S., Abhyankar, S., Hasanabba, D.E., Tsai, T.A., Eyre, M., Wang

Volltext bestellen